BACKGROUND: Up to 40% of childhood cancer survivors may experience neurocognitive impairment in 1 or more specific domains. As such, regular monitoring has been recommended for patients exposed to cranial irradiation and/or antimetabolite chemotherapy. This study reports the results of a questionnaire developed to identify those survivors who may be experiencing neurocognitive problems. METHODS: Participants for this study were 7121 members of the Childhood Cancer Survivor Study cohort (6739 survivors and 382 siblings). These participants completed a new neurocognitive questionnaire designed to assess functions commonly affected by cancer therapy, as well as a standard measure of emotional functioning. A measure of cognitive and emotional functioning was also completed on a subset of the patients roughly 7 years before the current questionnaire. Responses to the questionnaires among subgroups of survivors were then analyzed to examine the reliability and validity of the new neurocognitive questionnaire. RESULTS: Four reliable factors were identified that assessed task efficiency, emotional regulation, organization, and memory skills. These neurocognitive factors accurately discriminated survivors who were at "high risk" for neurocognitive dysfunction, because of neurologic abnormalities or a history of intensive focal cranial irradiation, from healthy "low-risk" survivors and siblings. CONCLUSIONS: The questionnaire demonstrated excellent reliability, as well as construct and discriminative validity. It appears to be a practical and efficient tool for monitoring neurocognitive outcomes in adult survivors of pediatric cancer. (c) 2008 American Cancer Society.
BACKGROUND: Up to 40% of childhood cancer survivors may experience neurocognitive impairment in 1 or more specific domains. As such, regular monitoring has been recommended for patients exposed to cranial irradiation and/or antimetabolite chemotherapy. This study reports the results of a questionnaire developed to identify those survivors who may be experiencing neurocognitive problems. METHODS:Participants for this study were 7121 members of the Childhood Cancer Survivor Study cohort (6739 survivors and 382 siblings). These participants completed a new neurocognitive questionnaire designed to assess functions commonly affected by cancer therapy, as well as a standard measure of emotional functioning. A measure of cognitive and emotional functioning was also completed on a subset of the patients roughly 7 years before the current questionnaire. Responses to the questionnaires among subgroups of survivors were then analyzed to examine the reliability and validity of the new neurocognitive questionnaire. RESULTS: Four reliable factors were identified that assessed task efficiency, emotional regulation, organization, and memory skills. These neurocognitive factors accurately discriminated survivors who were at "high risk" for neurocognitive dysfunction, because of neurologic abnormalities or a history of intensive focal cranial irradiation, from healthy "low-risk" survivors and siblings. CONCLUSIONS: The questionnaire demonstrated excellent reliability, as well as construct and discriminative validity. It appears to be a practical and efficient tool for monitoring neurocognitive outcomes in adult survivors of pediatric cancer. (c) 2008 American Cancer Society.
Authors: B Ziemus; O Baumann; R Luerding; R Schlosser; G Schuierer; U Bogdahn; M W Greenlee Journal: Neuropsychologia Date: 2007-02-23 Impact factor: 3.139
Authors: Brenda J Spiegler; Kimberly Kennedy; Ronnen Maze; Mark L Greenberg; Sheila Weitzman; Johann K Hitzler; Paul C Nathan Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Lonnie K Zeltzer; Christopher Recklitis; David Buchbinder; Bradley Zebrack; Jacqueline Casillas; Jennie C I Tsao; Qian Lu; Kevin Krull Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Yin Ting Cheung; Tara M Brinkman; Chenghong Li; Yasmin Mzayek; Deokumar Srivastava; Kirsten K Ness; Sunita K Patel; Rebecca M Howell; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2018-04-01 Impact factor: 13.506
Authors: Pinki K Prasad; Kristina K Hardy; Nan Zhang; Kim Edelstein; Deokumar Srivastava; Lonnie Zeltzer; Marilyn Stovall; Nita L Seibel; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin Krull Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: Peter M K de Blank; Michael J Fisher; Lu Lu; Wendy M Leisenring; Kirsten K Ness; Charles A Sklar; Marilyn Stovall; Chris Vukadinovich; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Cancer Date: 2016-01-11 Impact factor: 6.860
Authors: Tara M Brinkman; E Anne Lown; Chenghong Li; Ingrid Tonning Olsson; Jordan Gilleland Marchak; Margaret L Stuber; Stefanie Vuotto; Deokumar Srivastava; Paul C Nathan; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin R Krull Journal: Addiction Date: 2018-10-19 Impact factor: 6.526
Authors: S Cristina Oancea; Tara M Brinkman; Kirsten K Ness; Kevin R Krull; Webb A Smith; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: J Cancer Surviv Date: 2014-01-24 Impact factor: 4.442
Authors: Nancy R Clanton; James L Klosky; Chenghong Li; Neelam Jain; Deo Kumar Srivastava; Daniel Mulrooney; Lonnie Zeltzer; Marilyn Stovall; Leslie L Robison; Kevin R Krull Journal: Cancer Date: 2011-04-11 Impact factor: 6.860
Authors: Kelly M Kenzik; I-Chan Huang; Tara M Brinkman; Brandon Baughman; Kirsten K Ness; Elizabeth A Shenkman; Melissa M Hudson; Leslie L Robison; Kevin R Krull Journal: Neuropsychology Date: 2014-06-16 Impact factor: 3.295
Authors: Tara M Brinkman; Nan Zhang; Nicole J Ullrich; Pim Brouwers; Daniel M Green; Deo Kumar Srivastava; Lonnie K Zeltzer; Marilyn Stovall; Leslie L Robison; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: J E Sanders; P A Hoffmeister; B E Storer; F R Appelbaum; R F Storb; K L Syrjala Journal: Bone Marrow Transplant Date: 2009-08-31 Impact factor: 5.483